Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Understand the key risks the SP 500 presents to retirees and how volatility can impact withdrawal plans and long-term goals. This intro covers market exposure and practical safeguards.
17,139 articlesAs GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
A major enterprise contract could transform D-Wave from a hardware play into a recurring-revenue champion. This artic...
When rhythm pharma (rytm) releases earnings, investors get a window into revenue growth, cash health, and pipeline pr...
Arm Holdings sparked a notable February rally as revenue and earnings beat expectations and AI demand sharpened. This...
Investors are weighing the upside of autonomous trucking against cost, timing, and risk. This article breaks down the...
Nvidia is facing a mixed start to 2026, but the long-term case remains intact. This article explains why a 40% jump b...
MP Materials is catching attention from large buyers of stock as it moves to boost magnet production and solidify the...
Rivian is expanding beyond its trucks and SUVs into self-driving tech and ridesharing partnerships. This guide breaks...
Optimum (OPTU) is reshaping its strategy in 2026. This original analysis dives into the Q1 results, margins, and capi...
The semiconductor market could double by 2030 as AI, data centers, and EVs push demand higher. This guide breaks down...
Investors are asking what the next five years hold for XRP. This guide breaks down plausible paths, key catalysts, ri...
Beyond Meat faces headwinds, but a protein drinks turnaround catalyst could change the game. This article breaks down...